Clinical Trials Logo

Filter by:
NCT ID: NCT02914262 Completed - IBD Clinical Trials

Single Ascending Dose Study to Assess the Safety, Tolerability, PK and PD Effects in Male Volunteers

Start date: August 2016
Phase: Phase 1
Study type: Interventional

This will be a double-blind, randomized, placebo-controlled, single ascending dose, Phase I study in healthy male subjects.

NCT ID: NCT02913625 Completed - Hand Injury Clinical Trials

Retroclavicular Approach vs Infraclavicular Approach for Plexic Bloc Anesthesia of the Upper Limb

Start date: September 2016
Phase: N/A
Study type: Interventional

Locoregional anesthesia provides several advantages over general anesthesia in terms of postoperative pain, decreased postoperative opioid needs and reduced recovery time for patients undergoing orthopaedic surgery. For upper limb surgery, the coracoid infraclavicular brachial plexus block is generally preferred because of its simplicity and effectiveness but, needle visibility remains a challenge because of the angle between the ultrasound beam and the needle. The retroclavicular approach for brachial plexus anesthesia requires an angle between the needle and the ultrasound beam that is less steep than the angle required to perform an infraclavicular coracoid block. This approach has already been proven effective and safe in the past. The general objective is to provide a formal comparison between the retroclavicular approach and coracoid infraclavicular approach for brachial plexus anaesthesia. This study will delineate the differences between the two techniques.

NCT ID: NCT02913443 Completed - Clinical trials for Small Cell Lung Cancer

A Dose Finding and Expansion Study of RO7051790 Administered Orally in Participants With Relapsed, Extensive-Stage Disease Small Cell Lung Cancer (ED SCLC)

Start date: December 20, 2016
Phase: Phase 1
Study type: Interventional

This is a Phase I, open-label, multicenter study designed to assess the safety and tolerability of RO7051790 in participants with relapsed ED SCLC. This dose escalation and expansion study plans to determine the maximum tolerated dose and/or optimal biological dose as a recommended Phase 2 dose for RO7051790, based on the safety, tolerability, pharmacokinetic and pharmacodynamic profiles observed after oral administration of RO7051790.

NCT ID: NCT02913313 Completed - Broad Solid Tumor Clinical Trials

A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors

Start date: November 30, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of experimental medication BMS-986207 by itself, in combination with Nivolumab, and in combination with both nivolumab and ipilimumab in participants with solid cancers that are advanced or have spread.

NCT ID: NCT02913261 Completed - Clinical trials for Corticosteroid Refractory Acute Graft vs Host Disease

Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation

REACH2
Start date: March 10, 2017
Phase: Phase 3
Study type: Interventional

Assess the efficacy and safety of ruxolitinib compared to Best Available Therapy (BAT) in patients with corticosteroid-refractory acute graft vs. host disease (aGvHD) after allogeneic stem cell transplantation.

NCT ID: NCT02913157 Completed - Clinical trials for Multiple Sclerosis, Primary Progressive

Hydroxychloroquine in Primary Progressive Multiple Sclerosis

Start date: November 2016
Phase: Phase 2
Study type: Interventional

The purpose of this clinical trial is to determine if HCQ in a dose of 400mg daily can prevent worsening of walking ability in people PPMS. The number of participants in this study will be 35. A maximum of 42 people with PPMS will be included. The trial is funded through a private donation to the Hotchkiss Brain Institute MS Translational Clinical Trials Research Program and the University of Calgary. There is no sponsorship from the pharmaceutical industry.

NCT ID: NCT02913079 Completed - Physical Activity Clinical Trials

The Acute Impact of Sit-stand Desks on Post-meal Blood Sugar Levels

Start date: September 2016
Phase: N/A
Study type: Interventional

Context and Rationale: Uninterrupted sitting is associated with increased risk of diabetes, heart disease, and death, even among people who are physically active. These relationships are likely due to increases in post-meal blood sugar observed when people sit for long periods (e.g. > 1 hour) without interruption. In contrast to sitting, standing results in large reductions in post-meal blood sugar levels. Our group has recently shown that sit-stand desks result in large (e.g. 2.5 hour/day) reductions in occupational sitting time. Taken together, these findings suggest that sit-stand desks may help to reduce post-meal blood sugar levels. However, this has yet to be examined in the field. Theoretical Approach and Objectives: The objective of this randomized crossover study is to determine whether people have lower blood sugar when using a sit-stand desk, in comparison to a desk that can only be used while sitting. Methods and Procedures: Sixteen participants will be asked to wear a continuous glucose monitor to measure their blood sugar levels during 2 separate conditions. During one condition, they will be asked to use a sit-stand desk to sit and/or stand as much as they like during 1 workday. During the other condition, they will be asked to work at a seated desk for 1 workday. Participants will be provided with identical meals to eat during each of the two conditions. We hypothesize that participants will have lower blood sugar levels on the day when they use the sit-stand desk, in comparison to the day using a traditional seated desk. Significance and Future Use: If our results support this hypothesis, this would suggest that sit-stand desks may be a useful way to reduce blood sugar levels in people at risk for diabetes. This could also lead to larger population-based interventions studying the health impact of sit-stand desks.

NCT ID: NCT02912962 Completed - Adolescents Clinical Trials

Self-Regulation in Adolescents With FASD: The Efficacy of a Targeted Intervention

Start date: September 2016
Phase: N/A
Study type: Interventional

Fetal alcohol spectrum disorder (FASD) describes a collection of physical, mental, and behavioral disabilities that result from prenatal alcohol exposure (PAE). Individuals with FASD often struggle with self-regulation, or the ability to control thoughts, emotions and actions, which can lead to many long-term problematic life circumstances. This study aims to improve self-regulation abilities in adolescents, aged 11-17, with FASD using a targeted intervention. Researchers adapted the Alert Program®, a developed intervention targeting self-regulation in children, to be appropriate for an adolescent FASD population. Participants are split into two groups: an FASD intervention group, and an FASD waitlist group. These groups are compared on a variety of measures. These measures include cognitive measures (executive functioning, response conflict, inhibitory control, etc), behavioural measures (self-regulation, adaptive behaviour, etc), and physiological measures (cortisol and sleep). The FASD intervention group will be tested at baseline and once after the intervention, and lastly after an approximately 12-week wait following the intervention. The FASD waitlist group will be tested at baseline, after a three month wait period, and again after receiving the intervention. The investigators expect that the Alert program® will lead to significant improvements in participant's self-regulation abilities as evidenced by cognitive, behavioural, and physiological changes. Improving self-regulation in adolescents with FASD will reduce the high level of adverse outcomes experienced by adolescents with FASD, and help them have a successful transition into adulthood.

NCT ID: NCT02912923 Completed - Stroke Clinical Trials

Reaching in Stroke 3rd Phase

RISP3
Start date: September 14, 2016
Phase: N/A
Study type: Interventional

The project targets stroke survivors to investigate the effect of augmented feedback (using robotic force cues and visual feedback) and rewards (game scores), on their upper limb reaching patterns and trunk compensatory movements

NCT ID: NCT02911649 Completed - Breast Cancer Clinical Trials

Reducing Sedentary Behaviour With Technology

Start date: September 2016
Phase: N/A
Study type: Interventional

Cancer-related fatigue (CRF) can be experienced by individuals with Prostate Cancer (PC), which can have profound effects on their well-being. Although physical activity has been shown to improve CRF, the recommended levels are generally not met. Step count and distance traveled information can help individuals to increase their physical activity. Wearable technology (WEAR) provides the user with feedback of their physical activity which can motivate behaviour change. Similarly, education workshops (EDU) on the effects of sedentary behaviour and physical activity may also reduce sedentary behaviour. The objectives of this study are to evaluate the effects of WEAR and EDU on sedentary behaviour and CRF, and to explore the feasibility of WEAR in this population. Participants in this study will be randomly assigned into WEAR, EDU, WEAR+EDU, or control over a three-month intervention. Assessments at baseline, post-intervention and a 3-month follow up will evaluate CRF, quality of life and level of sedentary behaviour, and use of WEAR devices. The results from this study will provide evidence-based knowledge on the impact of WEAR and EDU on sedentary behaviour and CRF, and an understanding on the use of technology within the PC population. These results can shape the development of programming for CRF and the use of scale-able technology-based interventions/approaches in this population.